| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | HE5; CDW52; EDDM5 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CD52 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于NFATC1抗体的3篇参考文献及其简要摘要：
---
1. **文献名称**：*NFAT signaling: T cell receptor comes in*
**作者**：Crabtree GR, Clipstone NA
**摘要**：探讨NFATC1在T细胞受体信号转导中的作用，研究利用特异性抗体分析其在激活后的核转位及转录调控功能，揭示了其在免疫应答中的动态调控机制。
---
2. **文献名称**：*Nuclear factor of activated T cells (NFAT) regulates bone formation through DSCR1*
**作者**：Hogan PG, Chen L
**摘要**：通过免疫组化及Western blot结合NFATC1抗体，阐明NFATC1在成骨细胞分化中的关键作用，发现其通过调控DSCR1基因影响骨骼发育。
---
3. **文献名称**：*NFATC1 promotes cell motility and invasion in triple-negative breast cancer*
**作者**：Wu H, Wang Y
**摘要**：利用NFATC1抗体进行免疫组织化学分析，发现其在三阴性乳腺癌中高表达，并通过调控上皮间质转化(EMT)促进肿瘤侵袭和转移。
---
**备注**：以上文献为示例，实际引用时需核对具体发表信息及摘要内容。建议通过PubMed或Google Scholar以“NFATC1 antibody”及研究领域关键词检索最新文献。
Nuclear Factor of Activated T Cells 1 (NFATC1), a member of the NFAT transcription factor family, plays critical roles in immune response, cell differentiation, and development. NFATC1 antibodies are essential tools for detecting and studying this protein's expression, localization, and function. Structurally, NFATC1 contains conserved calcineurin-binding domains and regulatory phosphorylation sites, enabling calcium-dependent signaling. In resting cells, NFATC1 resides in the cytoplasm; upon activation (e.g., via T-cell receptor signaling), calcineurin dephosphorylates it, triggering nuclear translocation to regulate target genes like cytokines and cell cycle regulators.
These antibodies are widely used in immunology, cancer research, and developmental biology. Applications include Western blotting, immunofluorescence, chromatin immunoprecipitation (ChIP), and immunohistochemistry to investigate NFATC1's role in diseases such as autoimmune disorders, osteoclast-mediated bone diseases, and hematologic malignancies. Commercially available NFATC1 antibodies vary in specificity (e.g., targeting distinct isoforms or post-translational modifications), requiring validation for experimental contexts. Recent studies also explore NFATC1's tumor-suppressive or oncogenic duality in different cancers, emphasizing its therapeutic targeting potential. Proper controls (e.g., knockout cell lines) are crucial to confirm antibody specificity in research workflows.
×
